NRT6003 / Chengdu New Radiomedicine Technology - LARVOL DELTA

Phase I/II, first-in-human study of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma: Safety and early efficacy profiles. (ASCO 2026) - P1 | "According to the SPECT/CT results after treatment with NRT6003 injection, the median tumor absorbed dose was 429.93 Gy (range: 197.1 Gy-2827.7 Gy)... In this multicenter Y-90 SIRT study, treatment with Y-90 Carbon Microspheres demonstrated a favorable safety and efficacy were observed in the treatment of unresectable HCC, providing a highly promising treatment option."

Clinical • First-in-human • P1/2 data • Fibrosis • Gastroenterology • Hepatocellular Cancer • Hepatology • Immunology • Oncology • Solid Tumor

Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Active, not recruiting ➔ Completed

Trial completion • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • AFP

Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Second Affiliated Hospital of Guangzhou Medical University

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere (clinicaltrials.gov) - P3 | N=108 | Active, not recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatocellular Cancer • Oncology • Solid Tumor

Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Jun 2025 | Trial primary completion date: Oct 2025 ➔ Jun 2025

Trial completion • Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

Safety and Efficacy of TareSphere Injection and cTACE in Patients With Unresectable HCC (clinicaltrials.gov) - P3 | N=108 | Recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

A Multicentre, Prospective, Open-label Randomised Controlled Clinical Study Comparing the Efficacy and Safety of NRT6003 Injection and Traditional Meridian Embolism in Patients with Non-operable Hepatocellular Cancer in China (clinicaltrials.gov) - P3 | N=6 | Not yet recruiting | Sponsor: Zhongda Hospital

New P3 trial • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Safety and Efficacy of TareSphere Injection and CTACE in Patients with Unresectable HCC (clinicaltrials.gov) - P3 | N=108 | Not yet recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD.

New P3 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Safety and Efficacy of TareSphere in Patients with Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatocellular Cancer • Oncology • Solid Tumor

Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD.

New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor